Novartis Pharmaceuticals Canada Inc.
385 Bouchard Boulevard
24 articles with Novartis Pharmaceuticals Canada Inc.
Ilaris® receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease
The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease (AOSD) brings hope for Canadians living with this rare, debilitating, and sometimes life-threatening inflammatory disorder.
Alberta sites join network of certified centres to deliver CAR-T therapy, Kymriah (tisagenlecleucel)
Novartis Pharmaceuticals Canada Inc. is pleased to announce that two centres in Alberta have been certified in accordance with applicable requirements, making Kymriah® (tisagenlecleucel) available to certain leukemia and lymphoma patients.
Novartis' KISQALI (ribociclib) product monograph in Canada now includes MONALEESA-3 data demonstrating statistically significant improvement in overall survival in postmenopausal women with HR+/HER2- advanced breast cancer
KISQALI ® is currently the only CDK4/6 inhibitor that has demonstrated statistically significant improvement in overall survival (key secondary endpoint) with various endocrine treatment partners and the broadest spectrum of patients in two Phase III trials in advanced breast cancer .
Novartis' MONALEESA-7 KISQALI® (ribociclib) study demonstrated statistically significant improvement in overall survival in pre- and perimenopausal women with HR+/HER2- advanced breast cancer
KISQALI® is the first CDK4/6 inhibitor to show statistically significant improvement in overall survival (key secondary endpoint) in advanced breast cancer in pre- and perimenopausal women.
PIQRAY® is approved and now available in Canada as the first and only treatment specifically for patients with a PIK3CA mutation in HR-positive, HER2-negative advanced breast cancer
Approval is based on results from SOLAR-1, where PIQRAY® in combination with fulvestrant nearly doubled median progression-free survival (PFS) compared to fulvestrant alone
Initiated in late 2019, the Novartis Innovation Prize: Assistive Tech for Multiple Sclerosis (MS) identified and encouraged technology ideas from all over the world with the aim to improve mobility, accessibility and daily life for people living with MS
Novartis Pharmaceuticals Canada Inc. is pleased to announce that KISQALI® is now indicated when used in combination for the treatment of women with hormone receptor -positive, human epidermal growth factor receptor 2 -negative advanced or metastatic breast cancer regardless of their menopause status and in combination with various approved hormonal treatment options.
Novartis receives Health Canada approval for Mayzent™ (siponimod) to treat secondary progressive multiple sclerosis with active disease
Novartis Pharmaceuticals Canada Inc. is pleased to announce that Health Canada has approved MayzentTM for the treatment of adults with secondary progressive multiple sclerosis with active disease evidenced by relapses or imaging features characteristic of multiple sclerosis inflammatory activity, to delay the progression of physical disability.
Novartis Pharmaceuticals Canada Inc. is pleased to announce that British Columbia will now reimburse KISQALI® for eligible patients in combination with an aromatase inhibitor under its provincial public drug program.
Addition of KISQALI® to drug plan in Quebec expands access to treatment for metastatic breast cancer
Provincial reimbursement provides public access to treatment that may delay the progression of advanced breast cancer
Novartis Pharmaceuticals Canada Inc. Release: Canadians With Advanced Skin Cancer Share Their Disease Journey With Launch Of An Empowering Photo Series: Melanoma Through My Lens
This Is An Amended Media Release Further To Novartis Pharmaceuticals Canada Inc.'s ("Novartis") Media Release Issued On January 7, 2015 For Fluad Pediatric
Novartis Pharmaceuticals Canada Inc. Announces Results At 2014 American Thoracic Society International Conference For Once Daily Dual Bronchodilator Ultibro® Breezhaler® Versus Combination Therapy For COPD
Novartis Pharmaceuticals Canada Inc. Release: Bexsero®: First Vaccine To Prevent Meningococcal Serogroup B (MenB) Now Available In Canada
Novartis Pharmaceuticals Canada Inc. Receives Health Canada Approval For Ultibro Breezhaler ®, A Once-Daily Dual Bronchodilator For COPD
Health Canada Approves Novartis Pharmaceuticals Canada Inc.'s Bexsero*, The First Vaccine Available To Prevent Meningococcal Serogroup B (MenB)(1,2)
Novartis Pharmaceuticals Canada Inc. Release: New Study Confirms Seasonal Flu Vaccine Designed for Seniors Improved Protection Against Influenza?
Novartis Pharmaceuticals Canada Inc. Continues to Build Its COPD Pipeline and Presents New Data on Investigational Once-Daily QVA149 at ERS
Novartis Pharmaceuticals Canada Inc. Release: Now Available in Ontario, (Pr)SEEBRI* BREEZHALER*, a Long-Term Once-Daily Maintenance Treatment for Chronic Obstructive Pulmonary Disease (COPD)
Novartis Pharmaceuticals Canada Inc. Resumes Seasonal Influenza Vaccine Distribution as Health Canada Lifts Suspension